
News|Articles|February 23, 2026
Conference Preview: Late-Breaking Abstracts at ASCO GU 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look into the top data set to be presented at this year's ASCO GU Cancers Symposium in San Francisco, California.
Advertisement
Advertisement
The late-breaking abstracts (LBAs) at this year’s American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium offer an early look at data that may meaningfully shift clinical decision-making across urologic oncology. As the treatment landscape continues to evolve, particularly with the expansion of targeted therapies, antibody-drug conjugates, and perioperative immunotherapy strategies, this year’s LBA slate reflects a growing emphasis on biomarker-driven care and treatment intensification across disease states.
Related to this article

Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement

